Tirzepatide
Tirzepatide is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our weight loss category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | Tirzepatide |
|---|---|
| Classification | Dual GIP/GLP-1 receptor agonist |
| Peptide type | Synthetic 39-amino-acid peptide |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Molecular weight | Approximately 4813.5 g/mol |
| Structure | 39-amino-acid linear synthetic peptide based on the sequence of endogenous GIP, conjugated to a C20 fatty diacid moiety for albumin binding and extended activity |
| Purity | ≥98% (HPLC-verified, batch-by-batch) |
| Form | Lyophilised peptide powder, multi-dose research vials |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 45 mg, 60 mg |
| Reconstitution | Reconstitute using bacteriostatic water or sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct light. For long-term storage prior to reconstitution, freezing conditions are recommended. Storage conditions are confirmed on the Certificate of Analysis supplied with each order. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-08-26. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The registrational work sits in two named programmes: SURPASS in type 2 diabetes and SURMOUNT in weight management. SURPASS-2 was an open-label phase 3 trial against once-weekly semaglutide as an add-on to metformin, measuring change in HbA1c. SURMOUNT-1 tested 5, 10 and 15 mg once-weekly against placebo in adults with a body mass index at or above 30, or at or above 27 with weight-related complications and without type 2 diabetes, measuring percentage change in body weight. A 15-year medullary thyroid carcinoma registry and a milk-only lactation study were imposed as required post-marketing studies at original approval.
What is not established
The label's own limitations of use record that it has not been studied in people with a history of pancreatitis and is not indicated in type 1 diabetes. Paediatric use below age 10 was waived and ages 10 to 17 deferred, so no paediatric label claim exists.
What distinguishes Tirzepatide
It is a co-agonist at the GIP receptor as well as the GLP-1 receptor, which is a different pharmacological class from a GLP-1 receptor agonist and is how the European regulator characterises it. Calling it a GLP-1 agonist misstates the approved characterisation. It is also the only compound here whose registrational programme includes a head-to-head phase 3 trial against another compound in this same range, SURPASS-2 against once-weekly semaglutide.
Sources
- US FDA. NDA 215866 approval letter, MOUNJARO (tirzepatide) injection, 13 May 2022
- US FDA. NDA 217806 approval letter, ZEPBOUND (tirzepatide) injection, 2023
- US FDA. MOUNJARO prescribing information as originally approved, 2022
- European Medicines Agency. Mounjaro, EPAR
- Jastreboff AM et al. Rationale and design of the SURMOUNT clinical development programme
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
Tirzepatide in supply terms
Tirzepatide is registered under CAS 2023788-19-2, with the molecular formula C225H348N48O68 and a molecular weight of approximately 4813.5 g/mol, the largest single-chain peptide in this weight-loss grouping by mass. The 39-residue backbone is based on the endogenous GIP sequence and carries a C20 fatty diacid moiety conjugated onto the chain, a modification that sets it apart structurally from unmodified GIP peptides. The classification, dual GIP/GLP-1 receptor agonist, is a naming convention reflecting the two-receptor binding architecture built into the sequence, used in procurement documentation to separate it from single-target peptides. Purity is verified at 98 percent or higher by HPLC on a batch-by-batch basis. The compound is supplied as a lyophilised powder in multi-dose research vials, white to off-white before reconstitution, typically carried out with bacteriostatic water or sterile laboratory-grade water. This is the widest fill range in the catalogue: 5mg, 10mg, 15mg, 20mg, 30mg, 45mg and 60mg, a spread worth checking closely when comparing per-mg pricing between quotes, since smaller and larger fills rarely price linearly. Storage requires refrigeration at 2-8C away from direct light, with freezing recommended for extended holds prior to reconstitution. Certificate of Analysis paperwork accompanies each order and documents the verified conditions for that batch.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for Tirzepatide and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Weight Loss
| Compound | Identifier | Presentation |
|---|---|---|
| AOD-9604 | 221231-10-3 | Vials: 5 mg. Pre-filled pens: 5 mg |
| Cagrilintide | C194H312N54O59 | Vials: 5 mg, 10 mg. Pre-filled ... |
| Retatrutide | C221H342N46O68 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
| Semaglutide | 910463-68-2 | Vials: 2 mg, 5 mg, 10 mg, 15 mg... |
Questions
Supply, answered
Is Tirzepatide available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy Tirzepatide. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply Tirzepatide as a second source?
Yes. Terms are agreed per compound, so you can add Tirzepatide without moving anything else you buy elsewhere.
Request pricing for Tirzepatide
Indicative volume and delivery country is enough to start. We reply within one working day.